ArticleExperimental and therapeutic medicine2026
Stevens-Johnson syndrome induced by fluoroquinolones in a patient with colon cancer: A case report and literature review.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent severe cutaneous adverse drug reactions characterized by extensive mucocutaneous necrosis and epidermal detachment. While these conditions are most commonly observed in association with sulfonamides and β-lactams antibiotics, emerging evidence indicates that fluoroquinolones may be linked to ~4% of cases. The current study presents a rare case of levofloxacin-induced SJS in a 55-year-old male with metastatic colon cancer. A total of 8 days after initiating levofloxacin, the patient developed a generalized erythematous rash, oral mucosal ulcerations and conjunctival hemorrhage. Despite discontinuation of the drug and the administration of dexamethasone, progressive epidermal detachment ensued, affecting 16% of the total body surface area, along with new perianal and scrotal erosions. Laboratory findings revealed persistent hypoalbuminemia, progressive azotemia and elevated procalcitonin. Despite active management, the patient ultimately succumbed to fatal septic shock and multiorgan dysfunction syndrome. This rare case highlights the need for heightened caution in administering fluoroquinolones to oncologically complex patients diagnosed with advanced colorectal cancer with malignant ascites and hypoalbuminemia prior to fluoroquinolone exposure. Furthermore, the findings suggest that malignant ascites and hypoalbuminemia may serve as novel prognostic indicators in patients with SJS/TEN and abdominal malignancies. These observations are valuable for refining current risk stratification models and provide a more precise basis for clinical decision-making in complex oncological patients to improve outcomes in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.